Holen Sie sich die Stockscreener-App
3.91
0.26%
-0.010
Schlusskurs vom Vortag:
$3.92
Offen:
$3.99
24-Stunden-Volumen:
76,850
Relative Volume:
0.81
Marktkapitalisierung:
$309.72M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-18.50M
KGV:
-15.10
EPS:
-0.259
Netto-Cashflow:
$-11.89M
1W Leistung:
-1.26%
1M Leistung:
-5.78%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.87
$4.00
1-Wochen-Bereich:
$3.80
$4.06
52-Wochen-Spanne:
$3.55
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
Firmenname
Nervgen Pharma Corp
Sektor
Branche
Telefon
-
Adresse
-
Compare NGEN vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
3.91 | 310.51M | 0 | -18.50M | -11.89M | -0.259 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Nervgen Pharma Corp Aktie (NGEN) Neueste Nachrichten
NervGen Pharma Corp.(TSXV: NGEN) dropped from S&P/TSX Venture Composite Index - marketscreener.com
NervGen Pharma (NGEN.US) Income Statements, Balance Sheet & Cashflow - Longbridge
NervGen Pharma Stock Quote, Share Price, News and Analysis - Longbridge
NervGen Pharma: I See Promise, But The Clock Is Ticking (Rating Downgrade) (NASDAQ:NGEN) - Seeking Alpha
NGEN.CA Stock Price, Quote & Chart | NERVGEN PHARMA CORP (TSX-V:NGEN) - ChartMill
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange - Sahm
NervGen Pharma to delist shares from TSX - TipRanks
NervGen Pharma (NGEN) to Voluntarily Delist from TSX Venture Exc - GuruFocus
NervGen Pharma to Delist from TSX Venture Exchange, Keep Nasdaq Listing as NVG-291 Advances - TipRanks
NervGen appoints regulatory and patient advocacy executives By Investing.com - Investing.com Nigeria
NervGen Pharma proposes amendment to warrant terms - MSN
NervGen Pharma price target raised to C$6.75 from C$5 at Stifel - TipRanks
Nanogen appoints Ruff as Chief Regulatory Affairs Officer, McSherry as SVP - TipRanks
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP of Patient Advocacy - geneonline.com
NervGen appoints regulatory and patient advocacy executives - Investing.com
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs - The Manila Times
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory - GlobeNewswire
NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program - TipRanks
Spinal Cord Injury Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development - StreetInsider
NervGen Pharma (NGEN) Stock Analysis Report | Financials & Insights - Benzinga Japan
NGENFNervgen Pharma Corp Latest Stock News & Market Updates - Stock Titan
NervGen Pharma to Participate at Upcoming Investor Conferences - The Manila Times
How NervGen Pharma Corp. (9UA) stock reacts to weak economy2025 Dividend Review & Low Risk High Win Rate Picks - mfd.ru
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams - The Manila Times
NervGen Pharma appoints Dr. Adam Rogers as CEO and president By Investing.com - Investing.com Nigeria
Why NervGen Pharma Corp. (9UA) stock stays on buy listsInsider Selling & High Conviction Investment Ideas - mfd.ru
Why NervGen Pharma Corp. (9UA) stock could be next leader2025 Price Momentum & Growth Focused Stock Pick Reports - mfd.ru
NervGen Pharma to Present at Unite2Fight Paralysis 20th Annual Science and Advocacy Symposium - marketscreener.com
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium - The Manila Times
NervGen Pharma Secures $10M to Propel Nasdaq Listing and NVG-291 Development - MSN
NervGen Pharma appoints new president & CEO - MSN
NervGen Pharma appoints Dr. Adam Rogers as CEO and president - Investing.com
NervGen Pharma Confirms Adam Rogers as CEO With New Equity-Rich Employment Deal - TipRanks
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury - marketscreener.com
NervGen Pharma names Adam Rogers as CEO - The Pharma Letter
NervGen Pharma Confirms Adam Rogers as CEO to Steer Next Growth Phase - TipRanks
NervGen appoints Rogers as CEO to lead neuroreparative drug development By Investing.com - Investing.com Australia
NervGen Pharma Names Adam Rogers Permanent CEO to Drive Next Growth Phase - TipRanks
NervGen Pharma Appoints New CEO Adam Rogers - Intellectia AI
Adam Rogers Appointed CEO of NervGen Pharma to Advance Spinal Cord Injury Treatment Efforts - geneonline.com
NGEN: NervGen Pharma Appoints New CEO to Advance NVG-291 - GuruFocus
NervGen Pharma Names Adam Rogers as CEO - marketscreener.com
NervGen appoints Rogers as CEO to lead neuroreparative drug development - Investing.com
NervGen Pharma Corp appoints Adam Rogers as chief executive officer - marketscreener.com
Finanzdaten der Nervgen Pharma Corp-Aktie (NGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):